References

1. Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003.

2. Chiu BC, Weisenburger DD: An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 4: 161-168, 2003.

3. Groves FD, Linet MS, Travis LB, et al.: Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92:1240-1251, 2000.

4. Diebold J, Anderson JR, Armitage JO, et al.: Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 43:97-104, 2002.

5. Raetz E, Perkins S, Davenport V, et al.: B large-cell lymphoma in children and adolescents. Cancer Treat Rev 29:91-98, 2003.

6. Jaffe ES, Harris NL, Stein H, et al.: World Health Organization Classification of Tumours. In: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

7. de Leval L, Harris NL: Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 43:509-528, 2003.

8. Cheson BD, Horning SJ, Coiffier B, et al.: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999.

9. de Wit M, Bohuslavizki KH, Buchert R, et al.: 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12:29-37, 2001.

10. Mikhaeel NG, Timothy AR, Hain SF, et al.: 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11(suppl 1): 147-150, 2000.

11. Jerusalem G, Beguin Y, Fassotte MF, et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglu-cose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999.

12. Jerusalem G, Beguin Y, Fassotte MF, et al.: Persistent tumor 18F-FDG uptake after a few cycles of poly-chemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85:613-618, 2000.

13. Haioun C, Besson C, Lepage E, et al.: Incidence and risk factors of central nervous system relapse in histologi-cally aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous sys-

tant components of treatment for relapsed disease. The impact of the monoclonal antibody, rituximab, in both front-line and relapsed regimens is encouraging, and may change the long-term outcome of this disease. Recent data also has revived interest in dose intensity as a further way of improving treatment for large cell lymphoma. Ongoing research and development of new agents is critical, and the next decade promises to provide even more effective options for our patients.

tem prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 11: 685-690, 2000.

14. van Besien K, Ha CS, Murphy S, et al.: Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184, 1998.

15. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993.

16. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.

17. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.

18. Lossos IS, Czerwinski DK, Alizadeh AA, et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004.

19. Chen MG, Prosnitz LR, Gonzalez-Serva A, et al.: Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer 43:1245-1254, 1979.

20. Kaminski MS, Coleman CN, Colby TV, et al.: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104:747-756, 1986.

21. Sweet DL, Kinzie J, Gaeke ME, et al.: Survival of patients with localized diffuse histiocytic lymphoma. Blood 58:1218-1223, 1981.

22. Spicer J, Smith P, Maclennan K, et al.: Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma. Br J Cancer 90:1151-1155, 2004.

23. Miller TP, Dahlberg S, Cassady JR, et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998.

24. Miller TP, LeBlanc M, Spier CM, et al.: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724a, 2001.

25. Horning SJ, Weller E, Kim K, et al.: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22: 3032-3038, 2004.

26. Fillet G, Mounier N, Thieblemont C, et al.: Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin's lymphoma: results of the GELA LNH 93-4 study. Blood :337a, 2002.

27. McKelvey EM, Gottlieb JA, Wilson HE, et al.: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976.

28. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.

29. Fisher RI, Shah P: Current trends in large cell lymphoma. Leukemia 17:1948-1960, 2003.

30. Messori A, Vaiani M, Trippoli S, et al.: Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84:303-307, 2001.

31. Coiffier B, Haioun C, Ketterer N, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927-1932, 1998.

32. Tobinai K, Igarashi T, Itoh K, et al.: Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821-830, 2004.

33. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001.

34. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI: Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 46:1569-1573, 2005.

35. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.

36. Coiffier B: Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 31:7-11, 2004.

37. Sehn LH, Donaldson J, Chhanabhai M, et al.: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). Blood 102:88a, 2003.

38. Habermann TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006.

39. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003.

40. Dall'Ozzo S, Tartas S, Paintaud G, et al.: Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64:4664-4669, 2004.

41. Cartron G, Dacheux L, Salles G, et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002.

42. Tilly H, Lepage E, Coiffier B, et al.: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003.

43. Blayney DW, LeBlanc ML, Grogan T, et al.: Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and pred-nisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21: 2466-2473, 2003.

44. Pfreundschuh M, Trumper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.

45. Pfreundschuh M, Trumper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104: 626-633, 2004.

46. Coiffier B, Salles G: Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. Blood 104:1584-1585. [Author reply 1585-1586.]

47. Gutierrez M, Chabner BA, Pearson D, et al.: Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 18:3633-3642, 2000.

48. Wilson WH, Grossbard ML, Pittaluga S, et al.: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002.

49. Verdonck LF, van Putten WL, Hagenbeek A, et al.: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051, 1995.

50. Martelli M, Vignetti M, Zinzani PL, et al.: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. J Clin Oncol 14:534-542, 1996.

51. Kaiser U, Uebelacker I, Abel U, et al.: Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 20:4413-4419, 2002.

52. Haioun C, Lepage E, Gisselbrecht C, et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000.

53. Gianni AM, Bregni M, Siena S, et al.: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997.

54. Milpied N, Deconinck E, Gaillard F, et al.: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295, 2004.

55. Strehl J, Mey U, Glasmacher A, et al.: High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 88:1304-1315, 2003.

56. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al.: Standard chemotherapy with or without highdose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 93:22-30, 2001.

57. Fisher RI: Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. J Natl Cancer Inst 93:4-5, 2001.

58. Bos GM, van Putten WL, van der Holt B, et al.: For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 9:191-194, 1998.

59. Miller JB, Variakojis D, Bitran JD, et al.: Diffuse histio-cytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction. Cancer 47:748-756, 1981.

60. Lichtenstein AK, Levine A, Taylor CR, et al.: Primary mediastinal lymphoma in adults. Am J Med 68:509-514, 1980.

61. Lazzarino M, Orlandi E, Paulli M, et al.: Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 15:1646-1653, 1997.

62. Joos S, Otano-Joos MI, Ziegler S, et al.: Primary medi-astinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571-1578, 1996.

63. van Besien K, Kelta M, Bahaguna P: Primary mediasti-nal B-cell lymphoma: a review of pathology and management. J Clin Oncol 19:1855-1864, 2001.

64. Savage KJ, Monti S, Kutok JL, et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003.

65. Nguyen LN, Ha CS, Hess M, et al.: The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys 47:1281-1285, 2000.

66. Bieri S, Roggero E, Zucca E, et al.: Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. Leuk Lymphoma 35: 139-146, 1999.

67. Zinzani PL, Martelli M, Magagnoli M, et al.: Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 94:3289-3293, 1999.

68. Haioun C, Gaulard P, Roudot-Thoraval F, et al.: Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 12: 425-429, 1989.

69. Popat U, Przepiork D, Champlin R, et al.: High-dose chemotherapy for relapsed and refractory diffuse large

B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 16:63-69, 1998.

70. Sehn LH, Antin JH, Shulman LN, et al.: Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 91:717-723, 1998.

71a. Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995.

71b. Velasquez WS, McLaughlin P, Tucker S, et al.:

ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994.

72. Moskowitz CH, Bertino JR, Glassman JR, et al.: Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17: 3776-3785, 1999.

73. van Besien K, Rodriguez A, Tomany S, et al.: Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 27:397-404, 2001.

74. Celik I, Kars A, Guler N, et al.: Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas. Eur J Cancer 34:759-760, 1998.

75. Jermann M, Jost LM, Taverna C, et al.: Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 15:511-516, 2004.

76. Zelenetz AD, Hamlin P, Kewalramani T, et al.: Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 14 (suppl 1):i5-i10, 2003.

77. Moskowitz C: Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 49 (suppl 1):S9-S12, 2002.

78. Hamlin PA, Zelenetz AD, Kewalramani T, et al.: Age-adjusted International Prognostic Index predicts autol-ogous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-1996, 2003.

79. Kewalramani T, Zelenetz AD, Nimer SD, et al.: Rituximab and ICE as second-line therapy before autol-ogous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004.

80. Magni M, Di Nicola M, Devizzi L, et al.: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000.

81. Flinn IW, O'Donnell PV, Goodrich A, et al.: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:628-632, 2000.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment